Preventing Anaphylaxis With Acalabrutinib

Exclusion Criteria

• •Participants who have been on immunomodulatory therapies or oral corticosteroids within 1 month prior to enrollment
• •Participants with symptoms consistent with food reactions other than type 1 hypersensitivity
• •History of allergic reaction to acalabrutinib
• •History of idiopathic urticaria, dermatographism, idiopathic or unexplained anaphylaxis, or anaphylaxis (to foods or otherwise) resulting in intubation, prolonged hypotension, or neurological sequelae- History of cardiovascular disease
• •History of a bleeding disorder, or those currently taking blood thinners
• •History of stroke
• •History of gastrointestinal ulcer
• •History of cancer (other than skin cancer)
• •Positive HIV status or history of other immunodeficiency
• •Active or latent Hepatitis B or C infection based on laboratory testing
• •Currently pregnant or nursing
• •Current use of proton pump inhibitors (Note: participants currently receiving proton pump inhibitors who switch to H2-receptor antagonists or other antacids are eligible for enrollment to this study).
• •Active significant infection
• •Major surgical procedure within 28 days of enrollment
• •Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura
• •Difficulty swallowing oral medication, or significant gastrointestinal disease that would limit absorption of oral medication
• •Concurrent participation in another therapeutic clinical trial